StockData

AVITA Medical vs TELA Bio

RCEL and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RCEL and TELA compare

AVITA Medical is the larger company, worth 14 times as much as TELA Bio ($488M against $34.2M).

TELA Bio grew revenue faster over the last twelve months (6.1% versus 1.00% for AVITA Medical).

TELA Bio keeps more of each dollar of sales as profit, with a net margin of −51.5% compared with −57.0% at AVITA Medical.

TELA Bio scores higher on the StockData Score (5 against 3 for AVITA Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRCELTELA
Size and price
Market cap$488M$34.2M
Share price$15.77$0.762
Change, 1 year321%−23.7%
Change, 5 years11.8%−93.8%
Beta (5Y)1.952.04
Employees226218
StockData Score
Total score35 (better)
Valuation score01 (better)
Growth score22
Performance score11
Health score01 (better)
Dividend score00
Valuation
P/S6.4×0.4× (better)
FCF yield−5.0% (better)−92.4%
Growth
Revenue growth (TTM)1.00%6.1% (better)
Revenue growth, 5Y average67.2% (better)34.5%
Profitability
Gross margin81.6% (better)67.8%
Operating margin−46.6%−42.6% (better)
Net margin−57.0%−51.5% (better)
FCF margin−32.5% (better)−39.6%
Return on invested capital−261%−212% (better)
Financial health
Interest coverage−6.5×−4.9× (better)
Current ratio0.412.99 (better)
Altman Z-score−10.50−9.41 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.9%70.5%
Held by insiders2.7%41.0%
Insider net buying, 12 months$235K (better)$186K
Short interest, % of float–2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.